35
total announcements
500124.BO · 15 min delayed
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has informed that the USFDA completed a Pre-Approval Inspection (PAI) at its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, with three observations issued in a Form 483, which will be addressed within the stipulated timeline.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has informed that the USFDA completed a Pre-Approval Inspection (PAI) at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh, with two observations issued in a Form 483.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has announced the release of Q2FY27 results on October 23rd, 2026, along with an earnings call at 19:30 PM IST / 10:00 AM ET.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018, confirming the dematerialization of securities and listing on stock exchanges.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has received a penalty of $32,350.20 from the US Internal Revenue Service for misclassifying a fiscal year reference at the time of tax payment. The company states that there is no material impact on its financials, operations, or other activities.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has announced the closure of its trading window from September 24, 2026 to October 25, 2026, ahead of its board meeting on October 23, 2026 to consider unaudited financial results for the quarter ending September 30, 2026.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 23/10/2026 to consider and approve Unaudited Standalone and Consolidated Financial results for the quarter ending September 30, 2026.
Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Ltd has published a notice regarding loss of share certificates in the newspapers Business Standard and Nava Telangana on September 16, 2026. The company has reported that certain share certificates have been lost or misplaced and has invited the registered shareholders/claimants to apply for duplicate share certificates.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has informed that the USFDA has completed a records assessment at its API manufacturing facility in Mexico, with two observations noted, and the company will respond within the stipulated timeline.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has allotted 4,110 equity shares to eligible employees on exercise of stock options under ESOPs, as per Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has published a newspaper notice regarding loss of share certificates, and the company has made the notice available on its website and on the websites of the stock exchanges.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has disclosed a GMP inspection by the USFDA at its formulations manufacturing facility in Hyderabad, with four observations issued in a Form 483, which the company will address within the stipulated timeline.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has informed that the USFDA has classified the inspection outcome at its API manufacturing facility in Mirfield, West Yorkshire, United Kingdom as 'Voluntary Action Indicated (VAI)' and concluded that the inspection is officially closed.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from ICICI Prudential Mutual Fund.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has announced the resignation of Mr. Deepak Sapra as CEO, API and Services and Senior Management Personnel, effective November 12, 2026.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd has terminated its agreement with Novartis India Limited due to a change in controlling shareholding. The company will continue to commercialize the affected brands until September 30, 2026.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has terminated its agreement with Novartis India Limited due to a change in controlling shareholding of NIL. The company will continue to commercialize the affected brands until September 30, 2026.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has terminated its agreement with Novartis India Limited due to a change in controlling shareholding. The company will continue to commercialize the affected brands until September 30, 2026.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd. has received U.S. FDA approval for its rituximab biosimilar, a biosimilar to Rituxan, for the U.S. market. The approval further strengthens Dr. Reddy's growing global biosimilars portfolio and advances its biosimilars business in the United States.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has informed that the USFDA has completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, and has issued a Form 483 with three observations.